<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Patients undergoing maintenance hemodialysis are at high cardiovascular risk </plain></SENT>
<SENT sid="1" pm="."><plain>Lowering <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> with <z:chebi fb="0" ids="35664">statins</z:chebi> reduces the incidence rate of cardiovascular events in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, two randomized, prospective, placebo-controlled trials have been completed in hemodialysis patients that showed no significant effects of <z:chebi fb="0" ids="35664">statins</z:chebi> on cardiovascular outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: A post hoc analysis was conducted of the 4D (Die Deutsche <z:mp ids='MP_0002055'>Diabetes</z:mp> Dialyze) study to investigate whether <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> at baseline is predictive of cardiovascular events and whether the effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on clinical outcomes depends on <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: High concentrations of <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> by tendency increased the risks of cardiac endpoints and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="5" pm="."><plain>Concordantly, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> significantly reduced the rates of adverse outcomes in the highest quartile of <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (â‰¥145 mg/dl, 3.76 mmol/L) </plain></SENT>
<SENT sid="6" pm="."><plain>The hazard ratios and 95% confidence intervals were 0.69 (0.48 to 1.00) for the composite primary endpoint, 0.58 (0.34 to 0.99) for cardiac <z:hpo ids='HP_0011420'>death</z:hpo>, 0.48 (0.25 to 0.94) for <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo>, 0.62 (0.33 to 1.17) for nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, 0.68 (0.47 to 0.98) for <z:hpo ids='HP_0000001'>all</z:hpo> cardiac events combined, and 0.72 (0.52 to 0.99) for <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0000001'>all</z:hpo> causes, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>No such decrease was seen in any of the other quartiles of <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> at baseline </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> undergoing hemodialysis, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> significantly reduces the risk of fatal and nonfatal cardiac events and <z:hpo ids='HP_0011420'>death</z:hpo> from any cause if pretreatment <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> is &gt;145 mg/dl (3.76 mmol/L) </plain></SENT>
</text></document>